Lupin gets nod for Trientine Hydrochloride Capsules USP; stock up 1%

The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

May 22, 2020 08:05 IST India Infoline News Service

Lupin
Pharma major Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC.

The stock is currently trading at Rs893.55, up by Rs7.8 or 0.88% from its previous closing of Rs885.75 on the BSE.

The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Trientine Hydrochloride Capsules USP (RLD: Syprine) had an annual sale of approximately USD 86 million in the US, as per IQVIA MAT March 2020.

Related Story